Phase_I_trial_of_H65-RTA_immunoconjugate_in_patients_with_cutaneous_T-cell_lymphoma._H65-RTA_is_an_immunoconjugate_that_consists_of_the_A_chain_of_ricin_(RTA),_a_ribosomal-inhibiting_protein,_coupled_to_a_murine_monoclonal_antibody_(H65)_directed_against_the_pan-T-cell_antigen_CD5._The_CD5_antigen_is_heterogeneously_expressed_on_cutaneous_T-cell_lymphoma_tumor_cells,_but_is_not_expressed_on_normal_cells_except_lymphocytes._A_phase_I_trial_was_therefore_conducted_in_which_14_patients_with_cutaneous_T-cell_lymphoma_progressive_on_other_therapies_were_treated_with_up_to_three_cycles_of_H65-RTA._The_maximal_tolerated_dose_(MTD)_of_H65-RTA_was_0.33_mg/kg/d_administered_intravenously_for_10_days_as_defined_by_dyspnea_at_rest_at_higher_doses._Other_reversible_side_effects_included_myalgia,_mild_hypoalbuminemia_with_weight_gain,_pedal_edema,_fatigue,_fevers,_and_chills._Six_patients_received_more_than_one_cycle_of_H65-RTA_without_increased_side_effects_compared_with_the_first_cycle._Pharmacokinetic_analysis_showed_that_peak_serum_drug_levels_were_dose-dependent,_and_ranged_from_1.13_to_5.56_micrograms/mL,_with_a_terminal_half-life_ranging_from_1.0_to_2.9_hours._The_development_of_antibodies_against_the_immunoconjugate_was_associated_with_a_lower_peak_drug_level,_but_not_with_enhanced_side_effects._Partial_responses_lasting_from_3_to_8_months_were_documented_in_four_patients._Three_of_the_responding_patients_received_more_than_one_cycle_of_H65-RTA_in_the_presence_of_anti-immunoconjugate_antibodies._The_results_from_this_phase_I_trial_suggest_that_H65-RTA_is_an_active_drug_in_the_treatment_of_cutaneous_T-cell_lymphoma._The_immunoconjugate_may_be_safely_administered_repeatedly,_even_in_the_presence_of_anti-immunoconjugate_antibodies,_with_responses_noted._Additional_studies_at_the_MTD_are_needed_to_define_the_response_rate_in_this_disease.